SIRPA and neoplasm: Alternatively, directly targeting phagocytosis-inhibitory pathways, including the CD47–SIRPα axis, or activating innate sensing pathways through TLR or STING agonists, offers promising avenues for enhancing macrophage-mediated tumor clearance.